Roche Shares Might Struggle to Rise -- Market Talk

1316 GMT - Roche Holding has benefited from a strong share rally over the past year that left it trading at a premium to European peers, but it might be hard to stretch this much further, UBS analysts say in a research note. While the Swiss drugmaker's medium-term prospects remain intact, this is now better captured by consensus estimates and the company's valuation, the analysts say. Breast-cancer drug giredestrant could generate multibillion-dollar annual sales, according to UBS. But beyond giredestrant's launch, Roche investors have limited updates to look forward to next year, the analysts add. UBS cuts its recommendation to neutral from buy and lifts its target price to 420 Swiss francs from 376 francs. Shares fall 1.5% to 397.50 francs, having risen 53% over the past year. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

November 02, 2026 08:17 ET (13:17 GMT)